Investors May Lead Securities Fraud Lawsuit Against Aardvark Therapeutics
Law firm Glancy Prongay Wolke & Rotter LLP announces investors with losses have an opportunity to lead a securities fraud class action lawsuit against Aardvark Therapeutics.
The law firm Glancy Prongay Wolke & Rotter LLP has announced that investors who experienced losses in Aardvark Therapeutics, Inc. have an opportunity to lead a securities fraud class action lawsuit.
The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and prospects between February 10, 2025, and May 14, 2026. Specifically, it is claimed that the company did not disclose that its drug ARD-101 was less safe than represented to investors and that its clinical, regulatory, and commercial outlooks were overstated.
Investors seeking to serve as lead plaintiff must file a motion with the court by October 13, 2026. The law firm is encouraging affected investors to contact them to learn more about their rights and potential claims to recover losses.
Glancy Prongay Wolke & Rotter LLP is a law firm specializing in investor rights litigation. The firm has a track record of handling complex class action cases.